Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
JMV 2959 is a growth hormone secretagogue receptor type 1a ( GHS-R 1a ) antagonist with an IC 50 of 32 nM.
In Vitro
JMV 2959 is a growth hormone secretagogue receptor type 1a (GHS-R 1a ) antagonist with an IC 50 of 32 nM. JMV 2959 does not induce any intracellular calcium mobilization by itself. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
When administered alone, it does not increase food intake and does not significantly stimulate growth hormone (GH) release . JMV 2959 dose dependently decreases the startle response (F(3.42)=4.4, p<0.01) and increases %prepulse inhibition (PPI) (F(3.42)=3.9, p<0.05) in the prepulse inhibition paradigm. The alteration in the startle response is mainly due to a 27% decrease in the startle seen in the highest dose of JMV 2959 (6 mg/kg) compare to vehicle (p<0.05). 6 mg/kg JMV 2959 induces a significant suppression of locomotion on days 1 to 7 relative to baseline day 0 (F(7,49)=2.21, p<0.05). Results also reveal a significant interaction between JMV 2959 treatment and day (F(1,14)=4.397, p<0.05). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal administration
Two-hundred-gram male Sprague-Dawley rats are used in the study. The animals (n=15) are randomly assigned to an initial treatment dose or vehicle and subsequently receive all the different doses tested in a counter balanced design. Each test is separated by a 3- to 4-day-long washout period. The rats are given the injection of JMV 2959 (or vehicle) 17 min prior to being placed in the startle cages (i.e., 25 min prior to the first pulse). The doses of JMV 2959 used for the dose response are 1, 3, and 6 mg/kg . aladdin has not independently confirmed the accuracy of these methods. They are for reference only.
IC50& Target:IC50: 32 nM (GHS-R 1a )
| Isomeric SMILES | COC1=CC=C(C=C1)CN2C(=NN=C2[C@@H](CC3=CNC4=CC=CC=C43)NC(=O)CN)CCC5=CC=CC=C5 |
|---|---|
| PubChem CID | 16114404 |
| Molecular Weight | 254.29 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|